Health & Biotech
ECS Botanics is an Australian leader in low-cost medicinal cannabis production, utilising innovative cultivation methods to meet EU-GMP (Good Manufacturing Practice) standards.
Its pharmacy-grade manufacturing facility prioritises sustainability, supplying pharmaceutical-grade products to Australia, the UK, Germany, Switzerland, and New Zealand.
ECS holds one of five licences from the Therapeutic Goods Administration for PIC/S GMP (Pharmaceutical Inspection Convention and Pharmaceutical Inspection Co-operation Scheme) certified products and employs a capital-efficient B2B model in a prime cannabis growing region along the Murray River in Victoria, benefiting from optimal climate conditions.
This results in high-quality cannabinoid products while minimising environmental impact, making ECS Botanics a key player in the industry.
KEY PEOPLE
RELATED STOCKHEAD STORIES
Health & Biotech
ASX Health: 4D Medical jumps 16pc on lungs device rollout, Proteomics up 10pc on UK deal
Health & Biotech
ASX pot stocks tap the capital markets as ECS and Cann Global announce capital raisings
Stockhead TV
Q-Wrapz: Oriel Morrison interviews Alex Keach, MD of ECS Botanics Holdings (ASX:ECS)
Health & Biotech
ECS Botanics records six-fold revenue increase as global demand for its sustainably grown cannabis soars
Health & Biotech
ASX Health Stocks: Immuron jumps 19pc after lead COVID-19 drug benefits published in major journal
Explainers
CBD Oil: The ultimate investor’s guide to a potential $64 billion global market
Health & Biotech
Canngea attracted to ECS Botanics’ sustainably grown cannabis, inks deal
News
ASX Health Stocks: Medical imaging player Resonance Health leads the pack with FY21 revenue increase
Health & Biotech
Lean, mean and green: How ECS Botanics is capitalising on ‘explosive growth’ in medicinal cannabis
Health & Biotech
Supermarket giant Coles will stock ECS Botanics’ hemp seed oil
News
Quarterlies Top 5: Cannabis, micro investing and cars top today’s list
Health & Biotech
ASX Health Stocks: Chimeric gets licence for CAR-T from U-Pen, Acrux gets nod from the FDA
News
Market Highlights and 5 ASX Small Caps to watch on Wednesday
Health & Biotech
ECS Botanics jumps almost 5pc on $4.5 million Polish deal
Health & Biotech
ASX health stocks: 4D Medical leads after ramping up its game in the US
Health & Biotech
ECS boosts executive team with four staff hires as it pursues a global cannabis growth strategy
Health & Biotech